Astrazeneca Pharma India Ltd vs Sun Pharma Advanced Research Company Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8530 as of 18 May 16:01 . The P/E Ratio of Astrazeneca Pharma India Ltd is 0 as of March 2023 .The P/E Ratio of Sun Pharma Advanced Research Company Ltd is 0 as of March 2023 . The Market Cap of Astrazeneca Pharma India Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sun Pharma Advanced Research Company Ltd is ₹ 5823 crore as of March 2023 . The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ 8.45 crore as compare to the Sep '25 revenue of ₹ 7.87 crore. This represent the growth of 7.37% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Sun Pharma Advanced Research Company Ltd for the Dec '25 is ₹ -69 crore as compare to the Sep '25 ebitda of ₹ -65.71 crore. This represent the growth of 5.01% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Sun Pharma Advanced Research Company Ltd changed from ₹ -95.9 crore to ₹ -80.42 crore over 7 quarters. This represents a CAGR of -9.57% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Sun Pharma Advanced Research Company Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Limited (SPARC) is a clinical stage bio-pharmaceutical company engaged in creating new drugs and delivery systems.
The Company works on innovation and new product development for global markets.
They undertake projects in research and technology for new chemical entities (NCE's) or new molecules, and novel drug delivery systems (NDDS). Sun Pharmaceutical Advanced Research Company Limited was incorporated on March 1, 2006 as an innovative and development company.
It commenced operations on March 22, 2006.
As per Scheme of Arrangement, the entire business undertaking of the Innovative Research & Development including Novel Drug Delivery System (NDDS) Division of Sun Pharmaceuticals Industries' Research & Development Undertaking was transferred and vested into the Company effective from February 28, 2007.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Sun Pharma Advanced Research Company Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Sun Pharma Advanced Research Company Ltd?

Market cap of Astrazeneca Pharma India Ltd is 21,221 Cr while Market cap of Sun Pharma Advanced Research Company Ltd is 5,309 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Sun Pharma Advanced Research Company Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Sun Pharma Advanced Research Company Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Sun Pharma Advanced Research Company Ltd?

As of May 18, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8488.45. On the other hand, Sun Pharma Advanced Research Company Ltd stock price is INR ₹163.6.

How do dividend payouts of Astrazeneca Pharma India Ltd and Sun Pharma Advanced Research Company Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Sun Pharma Advanced Research Company Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.